Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-PRKACA Antibody (R1Q49)

Catalog #:   RHD25101 Specific References (9) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: IF, IHC, IP, WB
Accession: P17612
Overview

Catalog No.

RHD25101

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

IF: 1:50-1:200, IHC: 1:50-1:100, IP: 1:20, WB: 1:500-1:1000

Target

PRKACA, PKACA, PKA C-alpha, cAMP-dependent protein kinase catalytic subunit alpha

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P17612

Applications

IF, IHC, IP, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.

Clone ID

R1Q49

Data Image
  • Immunofluorescence
    Immunocytochemistry analysis of cAMP Protein Kinase Catalytic subunit (green) in Hela using cAMP Protein Kinase Catalytic subunit antibody,and DAPI(blue)
  • Immunohistochemical
    Immunohistochemistry analysis of paraffin-embedded Human colon cancer using cAMP Protein Kinase Catalytic subunit antibody. High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.
  • Western blot
    Western blot analysis of cAMP Protein Kinase Catalytic subunit in K562, C6, 3T3, Hela lysates using cAMP Protein Kinase Catalytic Subunit antibody.
References

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion., PMID:38606105

Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report., PMID:35537414

Gene fusions in gastrointestinal tract cancers., PMID:35239225

Histopathological and genetic characterization of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion: a case series., PMID:28405879

Double adrenocortical adenomas harboring independent KCNJ5 and PRKACA somatic mutations., PMID:27165862

FGFR1 and FGFR2 in fibrolamellar carcinoma., PMID:26259677

PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling., PMID:24909179

CDC25B acts as a potential target of PRKACA in fertilized mouse eggs., PMID:18633139

Changes in intracellular distribution and activity of protein phosphatase PP1gamma2 and its regulating proteins in spermatozoa lacking AKAP4., PMID:15385410

Datasheet

Document Download

Anti-PRKACA Antibody (R1Q49).pdf

 

$ 290
Product specifications
50 μg 290 100 μg 484

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-PRKACA Antibody (R1Q49) [RHD25101]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only